Home  »  Companies   »  Akero Therapeutics Inc. (NASDAQ: AKRO) Stock Could...

Akero Therapeutics Inc. (NASDAQ: AKRO) Stock Could plummet Again 17.26%

The trading price of Akero Therapeutics Inc. (NASDAQ:AKRO) closed higher on Friday, June 17, closing at $12.16, 17.26% higher than its previous close.

Traders who pay close attention to intraday price movement should know that it fluctuated between $10.19 and $12.98. In examining the 52-week price action we see that the stock hit a 52-week high of $30.53 and a 52-week low of $7.52. Over the past month, the stock has gained 39.13% in value.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Akero Therapeutics Inc., whose market valuation is $363.22 million at the time of this writing, is expected to release its quarterly earnings report Mar 14, 2022 – Mar 18, 2022. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.9 per share this quarter, however they have predicted annual earnings per share of -$3.34 for 2022 and -$3.6 for 2023. It means analysts are expecting annual earnings per share growth of -15.60% this year and -7.80% next year.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Akero Therapeutics Inc. 1 upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest AKRO has a 50% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned AKRO a recommendation rating is 4. Out of them, 1 rate it a Hold, while 3 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Akero Therapeutics Inc. (AKRO) as Underweight, while 0 advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

A quick review shows that AKRO’s price is currently 42.02% off the SMA20 and 19.98% off the SMA50. The RSI metric on the 14-day chart is currently showing 70.05, and weekly volatility stands at 13.75%. When measured over the past 30 days, the indicator reaches 9.48%. Akero Therapeutics Inc. (NASDAQ:AKRO)’s beta value is currently sitting at 0, while the Average True Range indicator is currently displaying 0.96. With analysts defining $26.00-$62.00 as the low and high price targets, we arrive at a consensus price target of $45.75 for the trailing 12-month period. The current price is about -113.82% off the estimated low and -409.87% off the forecast high, based on this estimate. Investors will be thrilled if AKRO’s share price rises to $47.50, which is the median consensus price. At that level, AKRO’s share price would be -290.63% below current price.

To see how Akero Therapeutics Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: AKRO stock’s performance was 17.26% in the latest trading, and -59.40% in the past year. Also in last trading session, the S&P 500 Index has surged 0.22%, while the Dow Jones Industrial also saw a negative session, down -0.13% on the day.

An evaluation of the daily trading volume of Akero Therapeutics Inc. (NASDAQ:AKRO) indicates that the 3-month average is 287.55K.

Currently, records show that 35.01 million of the company’s shares remain outstanding. However, since the stock’s price has seen -42.51% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]